Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015) [clinicaltrials:NCT00163475]

Bio2RDF uri

Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015) [clinicaltrials:NCT00163475]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00163475

Bio2RDF identifier

NCT00163475

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00163475

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00163475

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:2bfd02cc7a6d0fdea45d79b9df9e55de

brief summary [clinicaltrials_vocabulary:brief-summary]

Bronchial asthma is amo ...... effectiveness of roflumilast.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy and Safety of Roflumi ...... ma (12 to 70 y) (BY217/M2-015)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

mean change from randomization to endpoint in forced expiratory volume in one second. [clinicaltrials_resource:8c78ea62fa88f1dc9fff99fd4a725ed5]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

mean change from randomization to endpoint in forced expiratory volume in one second. [clinicaltrials_resource:02372d2219cc59d354f194913853953b]

mean change from randomization to endpoint in forced expiratory volume in one second. [clinicaltrials_resource:0d154caa66795fbcdc5e5c9b91159626]

mean change from randomization to endpoint in forced expiratory volume in one second. [clinicaltrials_resource:48e820e6069741ed4957bc01d2265c91]

mean change from randomization to endpoint in forced expiratory volume in one second. [clinicaltrials_resource:a5f110b471cfd9766f4f893118a0895f]

mean change from randomization to endpoint in forced expiratory volume in one second. [clinicaltrials_resource:a9a72b2baa0e6553e98d73ef23a96975]

mean change from randomization to endpoint in forced expiratory volume in one second. [clinicaltrials_resource:d1734520d0076b37d7427b6a489fd34c]

completion date [clinicaltrials_vocabulary:completion-date]

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00163475 [clinicaltrials_resource:99dc508d76c7c3f64c558cb373b077f8]

enrollment [clinicaltrials_vocabulary:enrollment]

511

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Roflumilast [clinicaltrials_resource:e1572455e6782204e10d9f6b068efab4]

keyword [clinicaltrials_vocabulary:keyword]

Asthma

http://www.w3.org/2001/XMLSchema#string

Roflumilast

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Takeda [clinicaltrials_resource:be0157d7addd538bdf1562821c5e86fc]

location [clinicaltrials_vocabulary:location]

ALTANA Pharma [clinicaltrials_resource:36d0103c8da18a9a53ec55ceb557afff]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00163475

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

The MOVE-study: Morning Versus ...... Weeks in Patients With Asthma

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

BY217/M2-015

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Dirk Bredenbroeker, MD [clinicaltrials_resource:d2e68538d008fb8e357deb33b817b627]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Belgium: Institutional Review Board [clinicaltrials_resource:56606f2d95d1f9467bef3deb6bcd7c8d]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

source [clinicaltrials_vocabulary:source]

Takeda [clinicaltrials_resource:be0157d7addd538bdf1562821c5e86fc]

start date [clinicaltrials_vocabulary:start-date]

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00163475 study design [clinicaltrials_resource:127794518b502b507612b1febc01f46a]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00163475

verification date [clinicaltrials_vocabulary:verification-date]

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00163475

http://www.w3.org/2001/XMLSchema#string

title

Efficacy and Safety of Roflumi ...... ma (12 to 70 y) (BY217/M2-015)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Efficacy and Safety of Roflumi ...... ) [clinicaltrials:NCT00163475]

@en